SMS Pharma Q3FY26 Results: Profit Declines to ₹233.38 Cr; Approves ₹7 Cr Investment
SMS Pharmaceuticals Limited reported Q3 FY26 results. Standalone net profit was ₹233.38 crore, down from ₹251.43 crore YoY. Consolidated net profit was ₹231.90 crore, down from ₹251.29 crore YoY. The company approved an investment of up to ₹7 crore in its subsidiary, SMS Peptides Private Limited.
The decrease in quarterly profit and the approval of a moderate investment in a subsidiary have a noticeable but not critical impact on the company's financial standing.
The company reported a decline in net profit for both standalone and consolidated results for the third quarter compared to the same period last year.
SMS Pharmaceuticals Limited announced its unaudited standalone and consolidated financial results for the third quarter and nine months ended December 31, 2025. The company's Board of Directors, in a meeting held on February 7, 2026, approved these results.
For the third quarter ended December 31, 2025, the standalone net profit after tax was ₹233.38 crore (₹2,333.80 lakhs), a decrease compared to ₹251.43 crore (₹2,514.30 lakhs) in the same quarter of the previous year. Total income from operations for the quarter stood at ₹210.45 crore (₹21,044.70 lakhs).
Consolidated, the net profit after tax for the quarter was ₹231.90 crore (₹2,318.95 lakhs), down from ₹251.29 crore (₹2,512.93 lakhs) in the prior year's corresponding quarter. The consolidated total income from operations was ₹210.45 crore (₹21,044.70 lakhs).
The Board also approved a further investment of up to ₹7 crore in its subsidiary, M/s. SMS Peptides Private Limited, to be executed in one or more tranches.
The board meeting commenced at 10:15 a.m. and concluded at approximately 01:45 p.m.
What to do with a filing like this
SMS Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by SMS Pharmaceuticals Limited. Read the original for the full detail.